Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Cancer Highlights

Protein Kinase Therapeutics in Oncology - Where to Commercialize?
This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications.

Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis
This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

Cancer Antibodies: Competitive Positioning for Success
This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

Cancer Vaccines: Aim and Shoot
This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type. For the purposes of this report, BioSeeker is focusing on therapeutic cancer vaccines and as such the commercialized and pipeline prophylactic agents have not been included.

The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody (mAb)-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry. By analyzing R&D pipelines and the platform technologies in use today, it is possible to better predict where the market will be in the next decade and to envisage which new innovative therapies will become market successes.

Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
There is a plethora of new anti-angiogenic drugs in development. The potential to block tumor growth and metastases by angiogenesis inhibition represents an intriguing therapeutic strategy for the treatment of cancer and never before have we seen as many anti-angiogenic drugs in clinical trials.

This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you.

The Drug Target Atlas of Apoptopic Drugs in Oncology
The ultimate goal of cancer research is to learn how to make cancer cells selectively die. Apoptosis is the type of death about whose genetically controlled pathways we know the most.

Apoptotic cell death can be triggered by many different cellular stimuli, resulting in activation of apoptotic signaling pathways including extrinsic, intrinsic, and mitochondrial pathways. The plethora of new potential therapeutic drugs has made selection and validation of novel molecular targets of paramount importance.

First in place, BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. This report, The Drug Target Atlas of Apoptopic Drugs in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new apoptopic drugs in oncology.

The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
All cancers arise as a result of the acquisition of a series of fixed DNA sequence abnormalities, mutations, many of which ultimately confer a growth advantage upon the cells in which they have occurred. Protein kinases have been implicated in many aspects of tumorigenesis and protein kinase inhibitors (PKIs) have there of arisen as a major therapeutic class of compounds for the treatment of cancer. The plethora of new potential therapeutic drugs have made selection and validation of novel molecular targets of paramount importance.

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions